Leerink

After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...

In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...

Leerink’s Geoffrey Porges pointed out in a note the meaningful catalysts that had been expected for Biogen Inc (NASDAQ: BIIB) “have passed, mostly positively, and generated some value for investors; the incremental catalysts from here look relatively limited.” The analyst...

Leerink upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) to Outperform from Market Perform, saying the stock appears to have fully consolidated and reflects reasonable expectations for the Exondys launch. The Backdrop Sarepta Therapeutics has received FDA’s accelerated approval for eteplirsen...

Shares of Sarepta Therapeutics Inc (NASDAQ: SPRT) were under heavy selling pressure following a concerning report released by Leerink's Joseph Schwartz. Schwartz completed a MEDACorp payor survey and the results suggest the reimbursement landscape for Sarepta's therapy for the treatment...

Analyzing the monthly immuno-oncology sales data, Leerink said Merck & Co., Inc. (NYSE: MRK)'s Keytruda is picking up speed, but Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo is flattish. Immuno-Oncology Market On Strong Wicket Analyst Richard Goss noted that Symphony Health sales showed...

Pharma sector was hit following the comments made by President-elect Donald Trump who alluded to potential tightening of industry regulation. At his first press conference since being elected, Trump said the pharmaceutical industry is “getting away with murder” in terms of product...

On Wednesday, TESARO Inc (NASDAQ: TSRO) announced it had received a complete response letter from the FDA for its candidate, Varubi, in chemotherapy-induced nausea and vomiting. Leerink’s Seamus Fernandez maintains an Outperform rating on the company. Temporary Setback According to Tesaro...

Illumina, Inc. (NASDAQ: ILMN) pre-announced its Q4:16 sales Monday above the consensus and the estimate, while guiding to 2017 revenue marginally above the consensus forecast at the midpoint. The EPS guidance is in line with the consensus. Leerink’s Puneet Souda maintains a Market Perform...

Despite the District Court’s ruling in favor of Amgen, Inc. (NASDAQ: AMGN) over cholesterol drug Praluent, Leerink believes the patent dispute with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) is far from over given the possibility of appeal by these firms and...

The FDA has approved Spinraza for the treatment of all types of spinal muscular atrophy. The approval comes six months earlier than expected and with a label that is “as broad as even the most optimistic patient or investor could have hoped for,” Leerink’s Geoffrey C. Porges said...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that Soliris has failed to meet primary endpoints in a Phase II/III study related to the prevention of delayed graft function in adult recipients of diseased-donor kidney transplants who have elevated risk of disease. Soliris failed to achieve...

Shares of Agios Pharmaceuticals Inc (NASDAQ: AGIO) plunged more than 20 percent as it discontinued the development of a blood disorder study after FDA opined that the drug no longer had an appropriate risk-benefit ratio. Agios was developing AG-519, its "backup" pyruvate kinase-R (PKR...

Leerink is encouraged with comments from Express Scripts Holding Company (NASDAQ: ESRX) that it's not too concerned about a Donald Trump presidency and potential repeal of ACA. CEO Tim Wentworth said in a guidance call it's "still too early to say" but he hasn't "seen...

A handful of companies issued financial guidance this week to their respective investment communities. United Technologies United Technologies Corporation (NYSE: UTX) said it expects to earn $6.30 to $6.60 per share in fiscal 2017 on revenue of $57.5 billion to $59 billion. This compares to Wall...